Centocor Inc and licensees Schering-Plough Corp, Mitsubishi Tanabe Pharma Corp 
and Janssen Pharmaceutical KK are developing golimumab, a fully human mAb 
antibody against TNFalpha, for the potential treatment of rheumatoid arthritis 
(RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and ulcerative 
colitis. Golimumab is currently in phase III clinical trials for RA, PsA and AS 
and preliminary data have shown an improvement in a number of physical 
functions, disease activity, productivity and quality-of-life measurements.